SLC7A5 and renal cell adenocarcinoma: Taken together, the combination of oxaliplatin and LAT1 inhibitor (JPH203) significantly enhanced the therapeutic effect of RCC tumors, which provides a potential solution for chemotherapy resistance for solid tumor.